Cargando…
COVID-19 and Fatty Liver Disorders
In late 2019, the world was shaken by the COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus—2 (SARS-CoV-2) infection became one of the main causes of illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342635/ https://www.ncbi.nlm.nih.gov/pubmed/37445349 http://dx.doi.org/10.3390/jcm12134316 |
_version_ | 1785072546212741120 |
---|---|
author | Guarino, Maria Cossiga, Valentina Cutolo, Francesco Maria Attanasio, Maria Rosaria Lieto, Raffaele Morisco, Filomena |
author_facet | Guarino, Maria Cossiga, Valentina Cutolo, Francesco Maria Attanasio, Maria Rosaria Lieto, Raffaele Morisco, Filomena |
author_sort | Guarino, Maria |
collection | PubMed |
description | In late 2019, the world was shaken by the COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus—2 (SARS-CoV-2) infection became one of the main causes of illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease. This scenario crosses with the metabolic liver disorders’ “pandemic”, caused by the exponential spreading of non-alcoholic fatty liver disease, which is now the most prevalent cause of chronic liver disease (CLD). The aim of this review is to analyze the key factors of the relationship between COVID-19 and the spectrum of fatty liver disorders (FLD), in terms of molecular mechanisms and clinical presentation which can predict a more severe course of the infection. In addition, this review will face the change in management of FLD during pandemics, with a central role of telemedicine, and the role of other interventions in preventing and treating severe infection in these subjects. |
format | Online Article Text |
id | pubmed-10342635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103426352023-07-14 COVID-19 and Fatty Liver Disorders Guarino, Maria Cossiga, Valentina Cutolo, Francesco Maria Attanasio, Maria Rosaria Lieto, Raffaele Morisco, Filomena J Clin Med Review In late 2019, the world was shaken by the COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus—2 (SARS-CoV-2) infection became one of the main causes of illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease. This scenario crosses with the metabolic liver disorders’ “pandemic”, caused by the exponential spreading of non-alcoholic fatty liver disease, which is now the most prevalent cause of chronic liver disease (CLD). The aim of this review is to analyze the key factors of the relationship between COVID-19 and the spectrum of fatty liver disorders (FLD), in terms of molecular mechanisms and clinical presentation which can predict a more severe course of the infection. In addition, this review will face the change in management of FLD during pandemics, with a central role of telemedicine, and the role of other interventions in preventing and treating severe infection in these subjects. MDPI 2023-06-27 /pmc/articles/PMC10342635/ /pubmed/37445349 http://dx.doi.org/10.3390/jcm12134316 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Guarino, Maria Cossiga, Valentina Cutolo, Francesco Maria Attanasio, Maria Rosaria Lieto, Raffaele Morisco, Filomena COVID-19 and Fatty Liver Disorders |
title | COVID-19 and Fatty Liver Disorders |
title_full | COVID-19 and Fatty Liver Disorders |
title_fullStr | COVID-19 and Fatty Liver Disorders |
title_full_unstemmed | COVID-19 and Fatty Liver Disorders |
title_short | COVID-19 and Fatty Liver Disorders |
title_sort | covid-19 and fatty liver disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342635/ https://www.ncbi.nlm.nih.gov/pubmed/37445349 http://dx.doi.org/10.3390/jcm12134316 |
work_keys_str_mv | AT guarinomaria covid19andfattyliverdisorders AT cossigavalentina covid19andfattyliverdisorders AT cutolofrancescomaria covid19andfattyliverdisorders AT attanasiomariarosaria covid19andfattyliverdisorders AT lietoraffaele covid19andfattyliverdisorders AT moriscofilomena covid19andfattyliverdisorders |